Printer Friendly

PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES THE INTRODUCTION OF TWO NEW PERFUSION CHROMATOGRAPHY INSTRUMENTS

 CAMBRIDGE, Mass., July 12 /PRNewswire/ -- PerSeptive Biosystems, Inc. (NASDAQ: PBIO) announced today that it has begun to sell its BioCAD(tm) 250 Workstation and BioCAD/SPRINT(tm), two new instruments for performing purification and analytical separations using its patented Perfusion Chromatography(R) technology.
 Designed for gram-quantity purification of biopharmaceuticals, BioCAD 250 is a fully-automated instrument with flow rates of up to 250 milliliters/minute, or 15 liters/hour, combined with an enhanced version of PerSeptive's proprietary BioCAD software. The BioCAD 250, along with PerSeptive's patented POROS(R) media, provides biopharmaceutical developers with the first bench-top instrument that has the functionality of conventional skid-mounted process chromatography systems.
 PerSeptive has designed the BioCAD/SPRINT to address the needs of the basic researcher in a cost-effective manner. SPRINT performs laboratory-scale purification and analysis of proteins, peptides, oligonucleotides and oligosaccharides in a 30 second to 3 minute time frame with PerSeptive's patented POROS chromatography media.
 Noubar B. Afeyan, Ph.D., chairman and CEO of PerSeptive, commented on these additions to PerSeptive's family of BioCAD Workstations: "Since our introduction of the BioCAD Workstation in September 1991, biotechnology and pharmaceutical companies have purchased our instrumentation in increasing quantities owing to the substantial productivity gains afforded by our technology. The BioCAD family now includes instrumentation geared to meet the purification and analysis needs of biotechnology scientists from the academic researcher to the protein chemist who must purify gram quantities of clinical-grade mater
 The BioCAD family of products now includes four different instruments: BioCAD/SPRINT for the research needs of molecular biologists, protein chemists and other academic researchers; BioCAD 20 for analytical separations; the versatile BioCAD 60 for both preparative and analytical applications, and BioCAD 250 for gram-quantity purification of clinical-grade material.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R) for high resolution separations of biomolecules 10 to 1,000 thousand times faster than conventional chromatography, ImmunoDetection(tm) for real-time immunoassays in a flow-through cartridge format and Rational Surface Design(tm), synthetic surfaces that bind biomolecules with the high specificity of antibodies.
 -0- 7/12/93
 /CONTACT: (Scientific contact) Noubar B. Afeyan, Ph.D., president and CEO; or (Investor contact) Robert A. Fein, senior vice president of finance; or Patricia F. Dimond, Ph.D., director of corporate development, all of PerSeptive Biosystems, Inc., all at 617-621-1787/
 (PBIO)


CO: PerSeptive Biosystems, Inc. ST: Massachusetts IN: MTC SU: PDT

CM -- NE002 -- 0269 07/12/93 09:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 12, 1993
Words:450
Previous Article:GRACO INC. NAMES TWO EXECUTIVES TO NEW POSITIONS
Next Article:RAYTHEON NAMES WEGNER SENIOR VP, CHAIRMAN AND CEO OF BEECH SUBSIDIARY
Topics:


Related Articles
PERSEPTIVE BIOSYSTEMS, INC., ANNOUNCES SETTLEMENT OF DISPUTE WITH FORMER PRESIDENT
PERSEPTIVE BIOSYSTEMS ANNOUNCES FISCAL YEAR 1992 RESULTS
PERSEPTIVE BIOSYSTEMS, INC.'S PROCESS DIVISION ANNOUNCES PILOT-SCALE SYSTEM MANUFACTURING AGREEMENT
PAUL J. SEKHRI JOINS PERSEPTIVE BIOSYSTEMS AS MARKETING DIRECTOR, ANALYTICAL PRODUCTS
PERSEPTIVE BIOSYSTEMS ANNOUNCES ELECTION OF DR. WILLIAM POUNDS TO ITS BOARD OF DIRECTORS
PERSEPTIVE BIOSYSTEMS ANNOUNCES AWARD OF PATENT FOR PERFUSIVE CHROMATOGRAPHY PARTICLES
PHARMACIA BIOTECH ASKS COURT FOR NON-INFRINGEMENT RULING
PERSEPTIVE BIOSYSTEMS SUES PHARMACIA AND SEPRACOR FOR PATENT INFRINGEMENT
REGNIER, PH.D NAMED CHIEF TECHNICAL OFFICER OF PERSEPTIVE BIOSYSTEMS; CO-INVENTOR OF PERFUSION CHROMATOGRAPHY WILL LEAD TECHNOLOGY EFFORTS
PRETRIAL RULING MADE IN PERSEPTIVE BIOSYSTEMS' PATENT INFRINGEMENT CASE AGAINST PHARMACIA BIOTECH AND SEPRACOR

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters